Ken Griffin Aura Biosciences, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 31,600 shares of AURA stock, worth $288,824. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,600

Previous 800 3850.0%

Holding current value

$288,824

Previous $6,000 4583.33%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$6.9 - $10.36 $16.1 Million - $24.2 Million	-2,337,654 Reduced 99.96%	1,011 $9,000
Q2 2024 Aug 14, 2024	SELL	$6.81 - $7.89 $9.11 Million - $10.6 Million	-1,337,607 Reduced 36.38%	2,338,665 $17.7 Million
Q1 2024 May 15, 2024	BUY	$7.09 - $9.24 $318,894 - $415,596	44,978 Added 1.24%	3,676,272 $28.9 Million
Q4 2023 Feb 14, 2024	BUY	$7.02 - $11.98 $8.05 Million - $13.7 Million	1,147,227 Added 46.18%	3,631,294 $32.2 Million
Q3 2023 Nov 14, 2023	BUY	$8.97 - $12.38 $210,669 - $290,756	23,486 Added 0.95%	2,484,067 $22.3 Million
Q2 2023 Aug 14, 2023	SELL	$8.51 - $13.33 $354,356 - $555,061	-41,640 Reduced 1.66%	2,460,581 $30.4 Million
Q1 2023 May 15, 2023	SELL	$8.88 - $12.11 $2.09 Million - $2.84 Million	-234,832 Reduced 8.58%	2,502,221 $23.2 Million
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $4.19 Million - $6.2 Million	424,735 Added 18.37%	2,737,053 $28.7 Million
Q3 2022 Nov 14, 2022	BUY	$13.1 - $20.34 $2,082 - $3,234	159 Added 0.01%	2,312,318 $41.9 Million

Others Institutions Holding AURA

# of Institutions

Shares Held

37.6M

Call Options Held

122K

Put Options Held

38.5K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $268M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account